Are two-centimeter breast cancers large or small?

BACKGROUND Node-negative breast cancers from 2 cm to 5 cm in size are classified as stage ii, and smaller cancers, as stage i. We sought to determine if the prognosis of women with a breast cancer exactly 2 cm in size more closely resembles that of women with a stage i or a stage ii breast cancer. METHODS Using a cohort of 4265 young women with breast cancer, we compared the 10-year breast cancer mortality rates for women who had a tumour 0.1-1.9 cm, exactly 2.0 cm, and 2.1-2.9 cm. RESULTS In the first 3 years after diagnosis, the survival pattern of women with a 2.0-cm breast cancer was nearly identical to that of women with a larger cancer (2.1-3.0 cm). From year 3 to year 10, the relative survival of women with a 2.0-cm breast cancer was improved and nearly identical to that of women with a smaller cancer. The 10-year survival rate was 89.3% for women with tumours less than 20 mm, 86.1% for women with tumours equal to 20 mm, and 81.2% for women with 21-mm to 29-mm tumours. CONCLUSIONS For young women with small breast cancers, the relative mortality from breast cancer is dynamic with increasing tumour size and varies with time from diagnosis.

[1]  P. Saigo,et al.  A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  C. Begg,et al.  The effect of changes in tumor size on breast carcinoma survival in the U.S.: 1975–1999 , 2005, Cancer.

[3]  S. Sabri,et al.  Reply to P.G. Tsoutsou et al and A.H. Trainer et al , 2011 .

[4]  C. Geyer,et al.  Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  S. Narod,et al.  Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence , 2007, Clinical Cancer Research.

[6]  M. Federico,et al.  Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent years , 2013, International journal of cancer.

[7]  N. Lin,et al.  Effect of very small tumor size on cancer-specific mortality in node-positive breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  S Hellman,et al.  Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  C. Lawton.  Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer , 2012 .

[10]  S. Singletary,et al.  Prognostic Factors in Node-Negative Breast Cancer: A Review of Studies With Sample Size More Than 200 and Follow-Up More Than 5 Years , 2002, Annals of surgery.

[11]  J. Crowe,et al.  Primary tumor size. Relevance to breast cancer survival. , 1992, Archives of surgery.

[12]  C. Sotiriou,et al.  Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures , 2007, Breast Cancer Research.

[13]  Keda Yu,et al.  Effect of large tumor size on cancer-specific mortality in node-negative breast cancer. , 2012, Mayo Clinic proceedings.

[14]  J. Wisell,et al.  Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures , 2010 .

[15]  Gord Glendon,et al.  Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer , 2012 .

[16]  T. Sellers,et al.  Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2. , 2013, Journal of the National Cancer Institute.

[17]  Melissa Bondy,et al.  Residual risk of breast cancer recurrence 5 years after adjuvant therapy. , 2008, Journal of the National Cancer Institute.

[18]  Douglas F. Easton,et al.  Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. , 2012, JAMA.

[19]  O. Olopade,et al.  Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy? , 2013, Breast Cancer Research and Treatment.